Visus Therapeutics, the US-based developer of a treatment for near vision loss, completed a $36m series A round yesterday featuring medical product group Johnson & Johnson.
The corporate participated through investment vehicle Johnson & Johnson Innovation – JJDC, investing together with hedge fund RTW Investments and multi-family office Wille.
Founded in 2019, Visus is developing an eye drop called Brimochol to correct for the loss of near vision associated with a condition known as presbyopia. The funding will be used to advance clinical development of Brimochol, which is designed to be taken once a day.
In September 2020, the startup closed the acquisition of all patent assets underpinning the development of Brimochol, which is based on research led by Herbert Kaufman, an ophthalmologist responsible for more than 15 innovations in the field of eyecare.
